SEC Form 4 · accession 0001209191-17-041311
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Bonderman
Director
Period of report
Jun 20, 2017
Accepted (ET)
Jun 22, 2017 · 2:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 20, 2017 | A | 2,410 | $0.00 | A | 4,360 | D | |
| Common StockF1 | holding | — | — | — | 2,408,084 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F2 | $91.21 | Jun 20, 2017 | A | 8,810 | A | — | Jun 19, 2027 | Common Stock | 8,810 | 8,810 | D |
Explanation of responses
- F1The securities are held in the name of the Bonderman Family Limited Partnership ("BFLP") of which Mr. Bonderman is a limited partner. Wildcat Capital Management, LLC ("Wildcat") has dispositive and voting power over the shares held by BFLP pursuant to the terms of an investment management agreement to which Wildcat, Mr. Bonderman and BFLP are parties. Mr. Bonderman disclaims beneficial ownership of such shares held by BFLP except to the extent of his pecuniary interest therein.
- F2The stock option shall vest in 12 successive equal monthly installments following the date of grant.